NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating

2025-11-16 10:30:00 ET

The last time I spoke about NewAmsterdam Pharma Company N.V. ( NAMS ) it was with respect to a Seeking Alpha article entitled " NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period ". With respect to this article, I wrote about the company preparing to release results from several of its phase 3 studies using its lead cholesteryl ester transfer protein [CETP] inhibitor obicetrapib for the treatment of patients at risk with cardiovascular disease [CVD] with elevated levels of low-density lipoprotein cholesterol [LDL-C] where existing therapies are not effective or tolerable. These three phase 3 studies in question are known as BROOKLYN, TANDEM, and BROADWAY. I'm happy to report that this company was able to report positive results from all three of these late-stage studies. The basis for this would be in terms of the development of obicetrapib as a monotherapy versus placebo, showing a 30% - 40% LDL-C lowering profile and then an even better 50% LDL-C lowering profile when this drug was combined with ezetimibe....

Read the full article on Seeking Alpha

For further details see: